In India, a genomic revolution is underway, with the utility of genetic testing becoming acknowledged in the prevention and diagnosis of diabetes, cardiovascular disease, cancer, and carrier status, among other conditions. Predictive genetic testing is seen as the next big weapon in the arsenal of cutting-edge healthcare innovation that may enhance patient outcomes without depending on a curative strategy, with the ability to uncover accurate preventative solutions to lay out treatment alternatives for patients. Let’s learn more about using genomics from industry leaders and experts.
According to new Mayo Clinic Proceedings research, roughly one out of every eight people who had predictive genomic testing discovered that they have a hereditary risk for health disease and may be able to manage it better with preventative therapy. Predictive genetic testing is projected to grow in demand as people adopt healthier lives and become more aware of new healthcare initiatives and breakthroughs.
Chronic illnesses have increased, while infectious diseases have decreased. Chronic disease treatments are increasingly concentrating on an individual’s genetic composition.
Transformation of Diagnosis, forecasting, and therapy
Genome sequencing grew more popular and proved in use during the COVID-19 pandemic when researchers succeeded in separating the SARS-COV-2 virus using this technology. This also resulted in Moderna developing an mRNA vaccine within 60 days of the sequence becoming accessible.
Researchers have identified potential in this field of study. Genome sequencing will eventually lead to personalized medicine regarding diagnosis, forecasting, and therapy. It could impact the drug discovery strategy.
People Also read – Genomics: The DNA Revolution You Can’t Ignore
Can genome sequencing be done at an affordable price in India?
Genome sequencing is rising in India. Despite falling behind China and Korea in the Asia Pacific area, several Indian startups and businesses have begun to research this new approach. Government agencies are also increasingly understanding the significance of these discoveries and turning to genomic research to give patients tailored treatment.
Singapore and India agreed to collaborate on genomic and bioinformatics research in 2022. The success of genomics innovation is dependent on a strong and adaptable digital infrastructure that supports the whole research program, from data processing and interchange to the capacity to interpret and store rising data quantities.
With government funding and initiatives, several businesses in India have emerged in recent years, offering a variety of services based on genetic sequencing.
Localization, R&D, and government support
Technological advances in next-generation sequencing (NGS) and decreased costs have resulted in an explosion of genetic data from clinical and scientific research.
Economies of scale will drive down costs, but large-scale democratization cannot happen without R&D and localization.
The cost of gene treatments is a serious concern in India. In terms of volume processing, China and Korea have an edge over India. A comparable SOP will be a win-win situation for the gene therapy sector, with the Indian government making the regulatory procedure simpler during the COVID-19 epidemic. Setting up labs and ensuring the accessibility of the necessary skill pools should be prioritized.
Challenges on the learning curve
The biggest problem with genetic testing appears to be raising awareness. When consumers and professionals understand the importance of genetic testing, they become vocal supporters. Most genetic tests are difficult to grasp by physicians, and efforts must be made to make the procedure easier to understand and actionable. Another difficulty is in the area of reimbursement.
The potential of genomics in future
The future of genomics appears to be bright. There has been considerable development in the advancement of novel sequencing technologies with never-before-seen characteristics in recent years. India is positioned to create new standards in the genomics sector, relying on a capable workforce, appropriate research funding, and timely government backing.
